YAP1 and neoplasm: Loss of Hippo pathway tumor suppressors or hyperactivation of YAP/TAZ can lead to tumor cell resistance to anticancer treatments, such as 5‐fluorouracil, paclitaxel, cisplatin, and doxorubicin.